Baudax Bio, Inc. (BXRXQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Feb 20, 2026
0.00%
Market Cap 52.00
Revenue (ttm) 1.27M
Net Income (ttm) -7.61M
Shares Out 52.46M
EPS (ttm) -1.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 129
Average Volume 3,389
Open 0.0000
Previous Close 0.0000
Day's Range 0.0000 - 0.0000
52-Week Range n/a
Beta 25.33
RSI 39.28
Earnings Date n/a

About Baudax Bio

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary bloc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 9
Stock Exchange OTCMKTS
Ticker Symbol BXRXQ
Full Company Profile

Financial Performance

In 2022, Baudax Bio's revenue was $1.27 million, an increase of 17.50% compared to the previous year's $1.08 million. Losses were -$58.80 million, 197.4% more than in 2021.

Financial Statements

News

There is no news available yet.